Healthcare Industry News: paclitaxel
News Release - June 15, 2012
Saladax Biomedical, Inc. Appoints Kevin M. Harter as President and Chief Executive OfficerBETHLEHEM, Pa., June 15, 2012 -- (Healthcare Sales & Marketing Network) -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kevin M. Harter has been appointed as the company's president and chief executive officer effective June 18, 2012.
Mr. Harter, who is a co-founder and senior vice president of the Life Science Greenhouse (LSG), a public-private life sciences investment partnership, has been serving as interim CEO of Saladax since January 2012.
Gregory Critchfield, M.D., chairman of the board at Saladax, commented, "After a careful search of highly qualified candidates over the last four months, we are delighted to have Kevin lead Saladax through its growth at this time. Kevin's expertise and connections to the pharmaceutical and investment communities will be invaluable in achieving the company's objectives. We look forward to Saladax's continued progress in financing its operations, commercializing its products and building strategic partnerships, as we achieve the company's mission to personalize the approach to patients."
Most recently, Mr. Harter has been serving as interim CEO of Saladax Biomedical. From 2007 to 2011, Mr. Harter served as executive chairman of Saladax, a LSG-portfolio company, where he led multiple, successful funding rounds and strategic deals for the company. Mr. Harter previously co-founded Keystone Medical Systems in 1990 and managed the company through significant growth until its acquisition by publicly-held Continental Medical Systems. Prior to Keystone, Mr. Harter held several positions within the Pennsylvania Blue Shield organization, including vice president, technology, and has contributed significantly to the development of the field of electronic claims, electronic medical records and physician practice management. He has held more than two dozen board seats in healthcare, technology and financial companies. Recognition for his professional and volunteer achievements include the Entrepreneur of the Year award and the Alumni Fellow and Philip Philip Mitchell Service Awards from the Pennsylvania State University. He holds a B.S. and MBA from Pennsylvania State University.
"I'm honored to be part of a team that is delivering on the promise of personalized medicine," said Mr. Harter. "Given the impressive caliber of the management team and compelling science behind Saladax's technology, I'm eager to work with this group that is having a real impact on patients. Healthcare is increasingly being enabled by information and Saladax's assays provide patients, providers and pharmaceutical companies with answers to important questions about their care and their drugs."
About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine. Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development. Three MyCare assays are currently offered to the oncology community: My5-FU™, Mypaclitaxel™ and MyDocetaxel™.
The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories. This technology capability also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.
The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania. Saladax is ISO 13485:2003 certified.
Source: Saladax Biomedical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.